35Pharma Closes Series C Financing to Advance Clinical Pipeline of Activin Inhibitors for Pulmonary Hypertension, Cardiometabolic Disease and Obesity 35Pharma Closes Series C Financing to Advance Clinical Pipeline of Activin Inhibitors for Pulmonary Hypertension, Cardiometabolic Disease and Obesity